A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS
Status:
Terminated
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a phase I, multicentre randomised, double-blind, placebo-controlled trial to assess
the safety and tolerability of continuous i.c.v. administration of sNN0029 infusion solution
at a dose of 4µg/day in patients with Amyotrophic Lateral Sclerosis (ALS).